New therapeutic advances in the management of progressive thyroid cancer

Endocrine-Related Cancer

Volumn 16, Issue 3, 2009, Pages 715-731

  Woyach, Jennifer A ^a   Shah, Manisha H ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 5 AZA 2' DEOXYCYTIDINE; AXITINIB; BORTEZOMIB; CAPECITABINE; CELECOXIB; COMBRETASTATIN; GEFITINIB; IMATINIB; IRINOTECAN; LENALIDOMIDE; MITOGEN ACTIVATED PROTEIN KINASE; MOTESANIB; PACLITAXEL; PAZOPANIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ROMIDEPSIN; SORAFENIB; STROMELYSIN; SUNITINIB; TANESPIMYCIN; THALIDOMIDE; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VORINOSTAT;

ALOPECIA; ANAPLASTIC CARCINOMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATAXIA; BLEEDING; BLOATING; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; CONSTIPATION; CYTOPENIA; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DNA METHYLATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ENZYME INHIBITION; FATIGUE; GALLBLADDER DISEASE; HAND FOOT SYNDROME; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; HYPOXIA; IC 50; INFECTION; INTESTINE PERFORATION; KERATOACANTHOMA; LARYNX EDEMA; LUNG EMBOLISM; MALAISE; MEDULLARY CARCINOMA; MINOR AFFECTIVE DISORDER; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PATHOGENESIS; PERICARDIAL EFFUSION; PERIPHERAL NEUROPATHY; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; PRURITUS; QT PROLONGATION; RADIOIMMUNOTHERAPY; RECURRENT LARYNGEAL NERVE PALSY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN BRUISING; SOMNOLENCE; STOMATITIS; SUDDEN DEATH; THROMBOCYTOPENIA; THROMBOSIS; THYROID CANCER; TRIACYLGLYCEROL BLOOD LEVEL; UNDIFFERENTIATED CARCINOMA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC PROTOCOLS; CARCINOMA; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; THYROID NEOPLASMS;

EID: 72749126837     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0335     Document Type: Review

References (106)

1. Ain KB, Lee C & Williams KD 2007 Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 17 663-670. (Pubitemid 47311556)
2. Ain KB, Lee C, Holbrook K, Dziba JM & Williams KD 2008 Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. Journal of Clinical Oncology 26 Supplement abstract 6027.
3. Alexandre J, Berthault-Cvitkovic F, Hilgers W, Yovine A, Weems G & Herait P 2003 Phase I and pharmacokinetic (PK) study of irofulven (IROF) and capecitabine (CAP) in combination using an intermittent schedule in advanced solid tumors. Proceedings of the American Society of Clinical Oncology 22 abstract 615.
4. Argiris A, Agarwala SS, Karamouzis MV, Burmeister LA & Carty SE 2008 A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Investigational New Drugs 26 183-188. (Pubitemid 351357713)
5. Bauer AJ, Patel A, Terrell R, Doniparthi K, Saji M, Ringel M, Tuttle RM & Francis GL 2003 Systemic administration of vascular endothelial growth factor monoclonal antibody reduces the growth of papillary thyroid carcinoma in a nude mouse model. Annals of Clinical and Laboratory Science 33 192-199. (Pubitemid 36705930)
6. Belfiore A, Gangemi P, Costantino A, Russo G, Santonocito GM, Ippolito O, Di Renzo MF, Comoglio P, Fiumara A & Vigneri R 1997 Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. Journal of Clinical Endocrinology and Metabolism 82 2322-2328. (Pubitemid 27287607)
7. Bergstrom JD, Hermansson A, Diaz de Stahl T & Heldin NE 1999 Non-autocrine, constitutive activation of Met in human anaplastic thyroid carcinoma cells in culture. British Journal of Cancer 80 650-656. (Pubitemid 29209825)
8. Bergstrom JD, Westermark B & Heldin NE 2000 Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Experimental Cell Research 259 293-299. (Pubitemid 30681534)
9. Braga-Basaria M, Hardy E, Gottfried R, Burman KD, Saji M & Ringel MD 2004 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. Journal of Clinical Endocrinology and Metabolism 89 2982-2988. (Pubitemid 38766397)
10. Brierley J, Tsang R, Glisson B, Kies M, Kane M, Haugen B, Litofsky D & Sherman S 2006 Bortezomib in patients with metastatic differentiated thyroid cancer: preliminary results of a multicenter phase II study. Thyroid 16 858.
11. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A & Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Research 62 7284-7290. (Pubitemid 36025251)
12. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM & Santoro M 2006 BAY 43-9006 inhibition of oncogenic RET mutants. Journal of the National Cancer Institute 98 326-334. (Pubitemid 43338212)
13. Chaplin DJ, Pettit GR & Hill SA 1999 Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Research 19 189-195.
14. Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM et al. 2006 Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. Journal of Clinical Oncology 24 1705-1711. (Pubitemid 46622142)
15. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW & Sidransky D 2003 BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute 95 625-627. (Pubitemid 36553510)
16. Cohen E, Needles B, Cullen K, Wong S, Wade J, Ivy S, Villaflor V, Seiwert T, Nichols K & Vokes E 2008a Phase 2 study of sunitinib in refractory thyroid cancer. Journal of Clinical Oncology 26 Supplement abstract 6025.
17. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P et al. 2008b Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. Journal of Clinical Oncology 26 4708-4713.
18. Cooney M, Savvides P, Agarwala S, Wang D, Flick S, Bergant S, Bhakta S, Lavertu P, Ortiz J & Remick S 2006 Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). In ASCO Annual Meeting, p 5580.
19. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP & Smallridge RC 2006 Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 25 2304-2317.
20. Davies L & Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. Journal of the American Medical Association 295 2164-2167.
21. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W et al. 2002 Mutations of the BRAF gene in human cancer. Nature 417 949-954.
22. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat P & Fiorentino MV 1991 Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. Journal of Endocrinological Investigation 14 475-480.
23. Droz J, Baudin E, Medvedev V, Delord J, Kane M, Kloos R, Ringel M, Kahatt C, Weems G & Shah M 2006 Activity of irofulven (IROF) combined with capecitabine (CAPE) in patients (pts) with advanced thyroid carcinoma: phase II international multicenter study (preliminary results). Journal of Clinical Oncology 24 Supplement abstract 15511.
24. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R & Talpaz M 2001 Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine 344 1038-1042. (Pubitemid 32267973)
25. Dvorakova S, Vaclavikova E, Sykorova V, Vcelak J, Novak Z, Duskova J, Ryska A, Laco J, Cap J, Kodetova D et al. 2008 Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Molecular and Cellular Endocrinology 284 21-27.
26. Dziba JM, Marcinek R, Venkataraman G, Robinson JA & Ain KB 2002 Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 12 1063-1070. (Pubitemid 36114813)
27. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F et al. 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. Journal of Clinical Endocrinology and Metabolism 93 682-687.
28. Frank-Raue K, Fabel M, Delorme S, Haberkorn U & Raue F 2007 Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. European Journal of Endocrinology 157 215-220. (Pubitemid 47233127)
29. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K & Takenoshita S 2003 BRAF mutations in papillary carcinomas of the thyroid. Oncogene 22 6455-6457. (Pubitemid 37281692)
30. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T & Kobayashi T 2004 Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145 2865-2875. (Pubitemid 38686236)
31. Garcia-Carbonero R & Supko JG 2002 Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clinical Cancer Research 8 641-661. (Pubitemid 34742090)
32. Gottlieb JA & Hill CS Jr 1974 Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. New England Journal of Medicine 290 193-197.
33. Goulart B, Carr L, Martins R, Eaton K, Kell E, Wallace S, Capell P & Mankoff D 2008 Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC). Journal of Clinical Oncology 26 Supplement abstract 6062.
34. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ & Voest EE 2007 A trial of imatinib therapy for metastatic medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 92 3466-3469. (Pubitemid 47435321)
35. Gullino PM 1978 Angiogenesis and oncogenesis. Journal of the National Cancer Institute 61 639-643.
36. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ et al. 2008 Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 26 4714-4719.
37. Haddad RI, Krebs A, Vasselli J, Paz-Ares L & Robinson B 2008 A phase II open-label study of vandetanib in patients with locally advanced or metastatic hereditary medullary thyroid cancer. Journal of Clinical Oncology 26 Supplement abstract 6024.
38. Hoelting T, Siperstein AE, Clark OH & Duh QY 1994 Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo. Journal of Clinical Endocrinology and Metabolism 79 401-408. (Pubitemid 24256526)
39. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G et al. 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clinical Cancer Research 13 1161-1170. (Pubitemid 46424056)
40. Hundahl SA, Fleming ID, Fremgen AM & Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995 (see comments). Cancer 83 2638-2648. (Pubitemid 29019586)
41. Ivan M, Bond JA, Prat M, Comoglio PM & Wynford-Thomas D 1997 Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14 2417-2423. (Pubitemid 27268160)
42. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, Xing S & Ledent C 1996 Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 137 375-378. (Pubitemid 26005013)
43. Jiang W, Hiscox S, Matsumoto K & Nakamura T 1999 Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Critical Reviews in Oncology/Hematology 29 209-248. (Pubitemid 29158969)
44. Kebebew E, Greenspan FS, Clark OH, Woeber KA & McMillan A 2005 Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 103 1330-1335.
45. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH, Rha SY, Kweon GR et al. 2006 An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. Journal of Clinical Endocrinology and Metabolism 91 4070-4076.
46. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE & Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Research 63 1454-1457. (Pubitemid 36373628)
47. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S & Fojo T 2001 Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. Journal of Clinical Endocrinology and Metabolism 86 3430-3435. (Pubitemid 32673517)
48. Kloos R, Ringel M, Knopp M, Heverhagen J, Hall N, Weldy L, Arbogast D, Collamore M & Shah M 2005 Preliminary results of phase II study of RAF/VEGF-R kinase inhibitor, BAY 43-9006 (sorafenib), in metastatic thyroid carcinoma. 13th International Thyroid Congress, Buenos Aires, Oct 30-Nov 4, 2005.
49. Kloos R, Ringel M, Knopp M, Hall N, King M, Stevens R, Liang J, Wakely P, Vasko V, Saji M et al. 2008 Phase II clinical trial of the multi-kinase inhibitor, Sorafenib, in metastatic thyroid cancer. Journal of Clinical Oncology 27 1675-1684.
50. V600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Research 65 4238-4245.
51. Kurebayashi J, Okubo S, Yamamoto Y, Ikeda M, Tanaka K, Otsuki T & Sonoo H 2006 Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemotherapy and Pharmacology 58 460-470. (Pubitemid 43999794)
52. van der Laan BF, Freeman JL & Asa SL 1995 Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 5 67-73.
53. Lennard CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL & Tuttle RM 2001 Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129 552-558. (Pubitemid 32374986)
54. Lewy-Trenda I & Wierzchniewska-Lawska A 2002 Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors. Polish Journal of Pathology 53 129-132. (Pubitemid 35278474)
55. Lin SY, Wang YY & Sheu WH 2003 Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. Clinical Endocrinology 58 513-518.
56. Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, Vasko V, El-Naggar AK & Xing M 2008 Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. Journal of Clinical Endocrinology and Metabolism 93 3106-3116.
57. Marsee DK, Venkateswaran A, Tao H, Vadysirisack D, Zhang Z, Vandre DD & Jhiang SM 2004 Inhibition of heat shock protein 90, a novel RET/PTC1-associated protein, increases radioiodide accumulation in thyroid cells. Journal of Biological Chemistry 279 43990-43997. (Pubitemid 39390707)
58. Martins RG, Rajendran JG, Capell P, Byrd DR & Mankoff DA 2006 Medullary thyroid cancer: options for systemic therapy of metastatic disease? Journal of Clinical Oncology 24 1653-1655.
59. Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF & Fagin JA 2006 Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Research 66 6521-6529. (Pubitemid 44085606)
60. Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, Richon VM, Marks PA & Mitsiades N 2005 Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clinical Cancer Research 11 3958-3965. (Pubitemid 40685618)
61. Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB & Mitsiades N 2006 Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. Journal of Clinical Endocrinology and Metabolism 91 4013-4021. (Pubitemid 44536879)
62. Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D et al. 2007 Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. Molecular Cancer Therapeutics 6 1070-1078. (Pubitemid 46554578)
63. Mrozek E, Kloos RT, Ringel MD, Kresty L, Snider P, Arbogast D, Kies M, Munden R, Busaidy N, Klein MJ et al. 2006 Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 91 2201-2204. (Pubitemid 43855005)
64. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T & Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. Journal of Clinical Endocrinology and Metabolism 88 4393-4397. (Pubitemid 37153748)
65. Nelkin BD & Ball DW 2001 Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncology Reports 8 157-160.
66. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A et al. 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. Journal of Clinical Endocrinology and Metabolism 88 5399-5404.
67. Paes JE & Ringel MD 2008 Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinology and Metabolism Clinics of North America 37 375-387 (viii-ix).
68. Palii SS, Van Emburgh BO, Sankpal UT, Brown KD & Robertson KD 2008 DNA methylation inhibitor 5-Aza-2′-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Molecular and Cellular Biology 28 752-771.
69. Patel A, Pluim T, Helms A, Bauer A, Tuttle RM & Francis GL 2004 Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Cancer Chemotherapy and Pharmacology 53 409-414. (Pubitemid 38553663)
70. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS et al. 2008 A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18 317-323.
71. Pierkarz R, Luchenko V, Draper D, Wright J, Figg W, Fojo A & Bates S 2008 Phase I trial of romidepsin, a histone deacetylase inhibitor, given on days one, three and five in patients with thyroid and other advanced cancers. Journal of Clinical Oncology 26 Supplement abstract 3571.
72. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S et al. 2006AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Research 66 8715-8721.
73. Porchia LM, Guerra M, Wang YC, Zhang Y, Espinosa AV, Shinohara M, Kulp SK, Kirschner LS, Saji M, Chen CS et al. 2007 2-Amino-N-{4-[5-(2-phenanthrenyl)- 3-(trifluoromethyl)-1H-pyrazol-1-yl]-phe nyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Molecular Pharmacology 72 1124-1131.
74. Provenzano MJ, Fitzgerald MP, Krager K & Domann FE 2007 Increased iodine uptake in thyroid carcinoma after treatment with sodium butyrate and decitabine (5-Aza-dC). Otolaryngology - Head and Neck Surgery 137 722-728. (Pubitemid 47632934)
75. Ravaud A, de la Fouchardière C, Courbon F, Asselineau J, Klein M, Nicoli-Sire P, Bournaud C, Delord J, Weryha G & Catargi B 2008 Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. Journal of Clinical Oncology 26 Supplement abstract 6058.
76. Di Renzo MF, Olivero M, Ferro S, Prat M, Bongarzone I, Pilotti S, Belfiore A, Costantino A, Vigneri R, Pierotti MA et al. 1992 Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene 7 2549-2553.
77. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J et al. 2007 Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncology 8 975-984. (Pubitemid 47629888)
78. Salgia R, Sherman S, Hong D, Ng C, Frye J, Janisch L, Ratain M & Kurzrock R 2008 A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). Journal of Clinical Oncology 26 Supplement abstract 3522.
79. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM & Santoro M 2006 BRAF is a therapeutic target in aggressive thyroid carcinoma. Clinical Cancer Research 12 1623-1629.
80. Santarpia L, El-Naggar AK, Cote GJ, Myers JN & Sherman SI 2008 Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 93 278-284.
81. Santoro M, Rosati R, Grieco M, Berlingieri MT, D'Amato GL, de Franciscis V & Fusco A 1990 The ret protooncogene is consistently expressed in human pheochromocytomas and thyroid medullary carcinomas. Oncogene 5 1595-1598. (Pubitemid 20383879)
82. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN et al. 2004 Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clinical Cancer Research 10 8594-8602.
83. Schlumberger M, Elisei R, Sherman S, Bastholt L, Wirth L, Martins R, Licitra L, Jarzab B, Pacini F, Daumerie C et al. 2007 Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with medullary thyroid cancer. 89th Annual Meeting of the Endocrine Society (ENDO 07): Toronto, ON.
84. Shaha AR, Shah JP & Loree TR 1997 Differentiated thyroid cancer presenting initially with distant metastasis. American Journal of Surgery 174 474-476.
85. Shan L, Nakamura M, Nakamura Y, Utsunomiya H, Shou N, Jiang X, Jing X, Yokoi T & Kakudo K 1998 Somatic mutations in the RET protooncogene in Japanese and Chinese sporadic medullary thyroid carcinomas. Japanese Journal of Cancer Research 89 883-886. (Pubitemid 28486812)
86. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T et al. 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. New England Journal of Medicine 359 31-42. (Pubitemid 351931094)
87. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH & DeConti R 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56 2155-2160. (Pubitemid 16236586)
88. Shimazaki N, Togashi N, Hanai M, Isoyama T, Wada K, Fujita T, Fujiwara K & Kurakata S 2008 Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model. European Journal of Cancer 44 1734-1743.
89. Smida J, Salassidis K, Hieber L, Zitzelsberger H, Kellerer AM, Demidchik EP, Negele T, Spelsberg F, Lengfelder E, Werner M et al. 1999 Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus. International Journal of Cancer 80 32-38. (Pubitemid 28559772)
90. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R & Sobrinho-Simoes M 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22 4578-4580. (Pubitemid 36920701)
91. Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW& Nelkin BD 2006 Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. Journal of Clinical Endocrinology and Metabolism 91 79-84. (Pubitemid 43069121)
92. Su Y, Tuttle R, Fury M, Ghossein R, Singh B, Herman K, Venkatraman E, Stambuk H, Robbins R & Pfister D 2006 A phase II study of single agent depsipeptide (DEP) in patients (pts) with radioactive iodine (RAI)-refractory, metastatic, thyroid carcinoma: preliminary toxicity and efficacy experience. Journal of Clinical Oncology 24 Supplement abstract 5554.
93. Tanaka K, Kurebayashi J, Sonoo H, Otsuki T, Yamamoto Y, Ohkubo S, Yamamoto S & Shimozuma K 2002 Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues. Surgery Today 32 761-768. (Pubitemid 35013690)
94. Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM & Sobrinho-Simoes M 2004 BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Journal of Pathology 202 247-251. (Pubitemid 38208663)
95. Uchino S, Noguchi S, Yamashita H, Sato M, Adachi M, Yamashita H, Watanabe S, Ohshima A, Mitsuyama S, Iwashita T et al. 1999 Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type. Japanese Journal of Cancer Research 90 1231-1237.
96. Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M & Fusco A 1995 RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 11 1207-1210.
97. Weinstein IB 2002 Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297 63-64.
98. Weinstein IB & Joe A 2008 Oncogene addiction. Cancer Research 68 3077-3080 (discussion 3080).
99. Wells S, Gosnell J, Gagel R, Moley J, Pfister D, Sosa J, Skinner M, Krebs A, Hou J & Schlumberger M 2007 Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. In 2007 ASCO Annual Meeting, Abst no. 6018.
100. Williams SD, Birch R & Einhorn LH 1986 Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treatment Reports 70 405-407. (Pubitemid 16130224)
101. Woyach J, Kloos R, Ringel M, Arbogast D, Collamore M, Zwiebel J, Grever M, Villalona-Calero M & Shah M 2008 Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 94 164-170.
102. Xing M 2005 BRAF mutation in thyroid cancer. Endocrine-Related Cancer 12 245-262.
103. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW & Sidransky D 2004 BRAF T1796A transversion mutation in various thyroid neoplasms. Journal of Clinical Endocrinology and Metabolism 89 1365-1368. (Pubitemid 38368438)
104. Xu X, Quiros RM, Gattuso P, Ain KB & Prinz RA 2003 High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Research 63 4561-4567. (Pubitemid 36951030)
105. Yeung SC, She M, Yang H, Pan J, Sun L & Chaplin D 2007 Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. Journal of Clinical Endocrinology and Metabolism 92 2902-2909. (Pubitemid 47236348)
106. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK & Chen CS 2004 From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Research 64 4309-4318. (Pubitemid 38802438)